Clinical trialNCT04066114CompletedPhase 1/PHASE2Interventional

Treg Modulation With CD28 and IL-6 Receptor Antagonists

SponsorNational Institute of Allergy and Infectious Diseases (NIAID)Enrollment24Kidney Transplant RecipientsLiving-Donor Kidney Transplant

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to evaluate the safety of using lulizumab pegol with tocilizumab, belatacept, and everolimus in kidney transplant recipients.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Flavio Vincenti, M.D.
University of California San Francisco School of Medicine: Transplantation
Principal Investigator
clinicaltrials.gov ↗
Sindhu Chandran, M.D.
University of California San Francisco School of Medicine: Transplantation
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Alabama School of Medicine: Transplantation
Birmingham, Alabama, United States
University of California San Francisco School of Medicine: Transplantation
San Francisco, California, United States
University of Colorado (uc) Health Transplant Center - Anschutz
Aurora, Colorado, United States
Northwestern Memorial Hospital: Transplantation
Chicago, Illinois, United States
University of Nebraska Medical Center: Transplantation
Omaha, Nebraska, United States
Duke University Medical Center: Transplantation
Durham, North Carolina, United States
Cleveland Clinic Foundation: Transplantation
Cleveland, Ohio, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Prednisone →Lymphocyte immune globulin, anti-thymocyte globulin →Belatacept →Everolimus →Lulizumab pegolMethylprednisolone →Mycophenolate mofetil →Mycophenolic acidTocilizumab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 11 Dec 2019
Primary completion: 14 Sept 2023
Completion: 14 Sept 2023
Last update posted: 9 Oct 2024
Registered enrollment: 24
Registry id: NCT04066114

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.